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Abstract
Background: How best to prioritise COVID-19 vaccination within and between countries has been a public health
and an ethical challenge for decision-makers globally. We reviewed epidemiological and economic modelling
evidence on population priority groups to minimise COVID-19 mortality, transmission, and morbidity outcomes.
Methods: We searched the National Institute of Health iSearch COVID-19 Portfolio (a database of peer-reviewed
and pre-print articles), Econlit, the Centre for Economic Policy Research, and the National Bureau of Economic
Research for mathematical modelling studies evaluating the impact of prioritising COVID-19 vaccination to
population target groups. The first search was conducted on March 3, 2021, and an updated search on the LMIC
literature was conducted from March 3, 2021, to September 24, 2021. We narratively synthesised the main study
conclusions on prioritisation and the conditions under which the conclusions changed.
Results: The initial search identified 1820 studies and 36 studies met the inclusion criteria. The updated search on
LMIC literature identified 7 more studies. 43 studies in total were narratively synthesised. 74% of studies described
outcomes in high-income countries (single and multi-country). We found that for countries seeking to minimise
deaths, prioritising vaccination of senior adults was the optimal strategy and for countries seeking to minimise
cases the young were prioritised. There were several exceptions to the main conclusion, notably that reductions in
deaths could be increased if groups at high risk of both transmission and death could be further identified.
Findings were also sensitive to the level of vaccine coverage.
Conclusion: The evidence supports WHO SAGE recommendations on COVID-19 vaccine prioritisation. There
is, however, an evidence gap on optimal prioritisation for low- and middle-income countries, studies that included
an economic evaluation, and studies that explore prioritisation strategies if the aim is to reduce overall health
burden including morbidity.
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Background
As of September 2021, over 6 billion vaccine doses have
been administered, but vaccines are still in limited supply
in many countries [1]. The question of which groups
should be prioritised for vaccination within countries and
between them has continued to present both a public
health and an ethical challenge to decision makers [2].
The World Health Organization (WHO) Strategic Ad-
visory Group of Experts on Immunisation (SAGE) work-
ing group on COVID-19 vaccines has provided guidance
to countries on the prioritisation of groups for vaccin-
ation while supply is limited. The guidance, based on the
WHO SAGE values framework for the allocation and
prioritisation of COVID-19 vaccines, seeks to ensure
equitable protection of human health across the globe,
and in particular, among those experiencing the greatest
risk and burden of COVID-19 [2, 3].
Epidemiological and economic models can provide an
assessment of the potential health and broader societal
impact of different prioritisation policies, and identify
the optimal groups to prioritise for vaccination, given
different public health objectives and scenarios. These
results can be considered alongside other decision cri-
teria to allocate vaccines both globally and within coun-
tries faced with a limited supply.
There was only a limited set of modelling results avail-
able to inform SAGE decision making at the end of 2020
(Fig. 1), but in early 2021, the evidence base greatly ex-
panded. The model results available at that time were
largely limited to high-income and high-transmission
settings such as the United States of America (USA) and
United Kingdom (UK). Models specifically addressing
low- and middle-income countries, as well as low-
transmission settings, were not available.
Fig. 1 WHO SAGE vaccine prioritisation recommendations under different supply scenarios during community transmission (adapted from the
WHO sage roadmap for prioritising uses of COVID-19 vaccines in the context of limited supply)
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We aimed to systematically review the epidemiological
and economic modelling literature on population groups
to prioritise for COVID-19 vaccination to minimise
COVID-19 mortality, transmission, and morbidity out-
comes, in order to inform prioritisation policy at both
the global and national levels. Our study is structured
around the policy questions that SAGE considered in
2020. In summary, these questions examined exploring
optimal allocation by age groups, occupational groups,
groups with comorbidities, and groups at higher risk of
infection, considering the impact on deaths, cases, mor-
bidity, and economic outcomes [3].
Methods
Search strategy and selection criteria
The systematic literature review was performed in line
with PRISMA guidelines (Fig. 2) [4]. We searched the
National Institute of Health (NIH) iSearch COVID-19
Portfolio on the 3rd of March 2021 (a database which
sources peer-reviewed articles from PubMed and pre-
prints from arXiv, bioRxiv, ChemRxiv, medRxiv, Pre-
prints.org, Qeios, Research Square, and SSRN). We
searched Econlit on the 3rd of March 2021, using the
advanced filters to include studies published between
2020 and 2021. To search these databases, we used a
Boolean strategy to combine keywords such as ‘model*’,
‘vacc*’, ‘econom*’, ‘cost’, and ‘COVID-19’. We contacted
the Centre for Economic Policy Research in the UK and
the National Bureau of Economic Research in the USA
and received their full datasets of studies on the eco-
nomics of COVID-19. Because of the lack of low- and
middle-income country (LMIC) studies in the first
search, an updated search narrowed to LMIC literature
was run on the 24th of September 2021. We also
Fig. 2 PRISMA flow diagram of study selection for the search conducted in March 2021 and in September 2021. HIC high-income country
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narrowed the search terms for the updated search to re-
trieve more relevant studies based on the experience of
the first search (Additional file 1: Table S1 for the full
search strategy and further details).
We included English language published or pre-print
studies that used mathematical modelling to assess the
impact of prioritising population target groups (either
within or between countries) for COVID-19 vaccination
on mortality, health (e.g. cases, quality adjusted life
years), health care (e.g. hospitalisations), and/or eco-
nomic (e.g. costs and cost-effectiveness) outcomes. We
excluded studies which did not use a mathematical
model to project the impact of COVID-19 vaccination,
where none of the parameters were determined by em-
pirical data (e.g. theoretical, non-empirical models), or
which modelled vaccination outcomes within a clinical
trial or a within-country small local setting, such as a
care home, rather than nation or district wide allocation.
For the updated search for LMIC literature, we applied
an additional criterion of excluding HIC studies.
Two researchers independently screened titles and ab-
stracts during the first round of screening. During the
second round, three researchers independently screened
titles/abstracts and full-text articles. All studies were
screened by at least two reviewers, where there were dis-
agreements about inclusion these were resolved in dis-
cussion with a fourth researcher. Three groups of two
researchers each independently extracted the data from
the included studies, with at least two groups reviewing
each study. Discordant entries between the sets of ex-
traction sheets were resolved by discussion between the
groups. Data were recorded in Microsoft Excel files sum-
marising the policy objectives, outcomes, characteristics
of the studies, the study conclusions and the conditions
under which the conclusions changed, i.e., sensitivity
analyses (see Additional file 2: full extraction sheet).
Studies explored the optimal prioritisation strategy
based on different policy objectives/outcomes (deaths,
cases etc.). We therefore extracted data and organised our
results tables by the objective used. Some studies used two
objectives to inform prioritisation (for example cases and
deaths). In these instances, we extracted and synthesised
both sets of results. A full list of outcomes modelled in the
included studies can be found in Table 1. We referred to
the Economic and Social Research Council’s guidance on
the conduct of narrative synthesis to aid data synthesis [5].
We therefore organised and grouped the textual results of
the studies so that we could identify patterns within and
between them. Synthesis was organised by the outcomes
being explored. Due to wide variation between the studies
in age group boundaries and other group classifications,
extracted data from the study conclusions on vaccination
priority groups were re-classified into broader population
categories to aid synthesis. The population group
categories considered were children/adolescents (ages 0–
18), young adults (ages 19–40), middle-aged adults (ages
41–64), seniors (65+), groups with comorbidities, high so-
cial contact groups, essential workers, health workers, and
geographic regions.
Studies had different combinations of comparators, so
we present results specifying the full range of compara-
tor populations assessed. Study setting was categorised
as high-income (HIC), upper middle-income (UMIC),
lower-middle income (LMIC), low income (LIC), multi-
region, or not specified, using World Bank classifications
for 2021 [6]. We extracted the modelling methods used,
and reviewed assumptions and model structure in detail
for the studies that did not align with the majority of
conclusions to identify if this was based on an excep-
tional method (referred to as ‘exceptions’). We also re-
port where sensitivity analyses generated results that
were contrary to main findings of the study.
Results
In the first search, our database search returned 2279
studies. After the removal of 459 duplicates, 1820 re-
cords were included in the title and abstract screening.
After title and abstract screening, 55 studies remained
for full-text screening. After assessing the full text of the
55 studies for eligibility, 36 studies were included in the
systematic review. After updating the search to look for
studies set in LMIC countries having identified this as
the predominant gap in the literature, 7 more studies
were included (Fig. 2).
Study characteristics are summarised in Table 1. All
the reviewed studies used models that captured trans-
mission between individuals, with deterministic com-
partmental models being most common (28/43).
However, agent-based models (6/43), stochastic com-
partmental models (4/43), a delay differential equation
model (1/43), and a linear model (1/43) were also
used. Studies most commonly used a SEIR (Suscep-
tible, Exposed, Infected, Recovered) (12/43) or Ex-
panded SEIR (19/43) natural history. Most of them
were set in a HIC (26/43); there were few single-
country UMIC (3/43) and LMIC (5/43) studies. There
were no single-country studies in a LIC setting. Only
a few (6/43) looked at more than one country and
two did not explicitly state the study setting. Most
studies explored multiple policy objectives/outcomes
regarding prioritisation: 34/43 investigated strategies
to minimise deaths, 27/43 investigated minimisation
of cases, 11/43 hospitalisations, 1/43 quality adjusted
life years (QALYs), 1/43 disability adjusted life years
(DALYs), and 3/43 years of life lost (YLLs). Only 2/
43 considered economic outcomes, such as financial
or economic costs, in relation to prioritisation.
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Prioritisation to minimise deaths
Table S2 (Additional file 1) summarises the study con-
clusions highlighting the priority group and all the com-
parators included in each study (see the ‘Methods’
section for how we defined population group categories).
Most studies included seniors in the priority group.
Nineteen studies recommended that seniors should be
prioritised for vaccination to minimise deaths [7–25].
One study recommended prioritising seniors with co-
morbidities [26], and six studies recommended vaccinat-
ing seniors at the same time as another priority group
(middle-aged adults, the highest social contact group,
young and middle-aged adults who are in high contact
with them, young adults with partial vaccine dose, and
health workers) [27–32].
Ten studies did not find that prioritising the groups at
highest risk of mortality (seniors or people living with
comorbidities) minimised deaths (for a summary of
these studies see Additional file 1: Table S3) [29, 30, 33–
40]. These ‘exceptional’ studies instead found that priori-
tising groups with a higher risk of infection would lead
to fewer deaths; in other words, that the indirect protec-
tion from lower transmission outweighs the benefits
from direct protection from vaccines for those at the
highest risk of mortality. The group at high risk of infec-
tion were defined as those with higher contact rates, e.g.
a synthetic population with 3–10 times the average
number of contacts of the age groups 30–39 [29], indi-
viduals with an expansive social network [37, 38], and
individuals with essential worker status [33, 34]. In
addition, two studies defined young adults as the group
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HIC, UMIC, LMIC 1





Agent-based (stochastic or deterministic) 6
Stochastic, compartmental 4
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Age, comorbidities, vaccination status 1
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Loss of economic benefits 1




Net present value of damages (VSL & DALYs) 1
Infection attack rate 2
Peak infections 1
Risk of new wave 1
Life-years gained 1
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Net monetary benefits 1
Effective reproductive number 1
Herd immunity 1
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with the highest social interactions and therefore at
higher risk of infection [35, 40]. One study examined
vaccination of individuals that had high levels of inter-
action with seniors [30].
One of the ten exceptional studies concluded that the
non-vulnerable group should be prioritised for vaccin-
ation compared to the group with comorbidities [36]. In
this study, the authors state they assumed that ‘the time
required to vaccinate the vulnerable group is identical to
that of the much larger non-vulnerable group’. Finally,
one study recommended prioritising vaccination through
the use of serological testing to achieve the greatest re-
duction in COVID-19-related deaths [41].
Prioritisation to minimise COVID-19 cases
Table S4 (Additional file 1) summarises the study con-
clusions. The largest proportion of the selected studies
(N=27) investigated optimal vaccine prioritisation strat-
egies to minimise COVID-19 cases. Of these, seven stud-
ies recommended young and middle-aged adults [10, 12,
15, 16, 17, 20, 28], three young adults [23, 25, 39], and
two young adults and children [27, 32]. One study rec-
ommended young people at the same time as another
priority group (seniors at full vaccine dose and young
adults at partial dose) [31].
Seven studies recommended vaccination prioritisation
based on social or occupational interactions compared
to age group prioritisation [14, 33, 34, 37, 38, 42, 43]. Of
these, three studies recommended prioritising essential
workers to minimise cases [14, 33, 34], and four studies
recommended prioritising high social contact adults
compared to other age groups [37, 38, 42, 43].
Two studies recommended prioritising vaccination
using serological testing to prioritise antibody-
negative individuals compared to not using serological
testing [41, 44]. Two studies investigated allocation
between geographic areas of disease burden—the first
recommended that the geographic area with lower
disease burden should be prioritised for vaccination,
whereas the second recommended that the geographic
area with the highest disease burden should be priori-
tised [45–46].
There were a few studies concluding differently to
the majority recommendations on minimising cases
(for a summary of these studies see Additional file 1:
Table S5). Three studies found that scenarios target-
ing seniors [13, 18, 31] led to the highest reduction
in cases. However, two of those studies did not have
a comparator that modelled those strategies com-
parted to more socially interactive populations [18,
31]. Chhetri et al. found very small differences be-
tween scenarios, and the conclusion was not reported
in the “Results” section [13].
Prioritising other outcomes
Studies investigating strategies to minimise hospitalisa-
tions from COVID-19 tended to reach similar conclusions
to studies investigating deaths (N=11). Eight studies rec-
ommended prioritising seniors [8, 15, 25, 16, 43, 47], se-
nior- and middle-aged adults [27], or seniors and the high
social contact group [29] for vaccination compared to
other age and occupational groups. Four studies con-
cluded differently from the majority of the hospitalisation
outcome studies [37, 38, 44, 48]. Two recommended
prioritising the high social contact group compared to
prioritising senior adults [37, 38]. One study recom-
mended prioritising vaccination by serological testing
compared to no serological testing [44]. One study recom-
mended giving equal priority to all age and risk groups
compared to a targeted age-based prioritisation [48].
A few studies investigated the optimal vaccination strat-
egy when maximising QALYs, DALYs, or YLLs. One
study modelled a vaccination prioritisation strategy to
minimise QALY losses [11]. The authors concluded that
the most effective strategy to minimise QALY losses is to
prioritise seniors for vaccination compared to other age
groups, groups with comorbidities, and no group priori-
tisation. Three studies investigated within-country vaccine
prioritisation strategies for minimising YLLs [12, 28, 34].
Two studies recommended prioritising seniors for vaccin-
ation to minimise YLLs [12, 34], and the other recom-
mended prioritising middle aged adults and seniors [28].
One study modelled the impact of COVID-19 vaccination
on DALYs [19]. The authors found that the amount of
DALYs averted under a base vaccination strategy which
prioritised seniors was stable to a scenario where everyone
over 15 years old is vaccinated [19].
One study considered the cost-effectiveness of
COVID-19 vaccination [19]. The authors found that the
strategy of prioritising seniors for vaccination was simi-
larly cost-effective to vaccinating all individuals over 15
years old [19].
One study investigated prioritisation strategies for
optimising the incremental net monetary benefit (iNMB)
of vaccination, i.e. the net economic gain from vaccin-
ation including both costs saved and monetised health
gains [48]. The authors concluded that giving equal pri-
ority to all age and risk groups was most optimal com-
pared to prioritising seniors, high risk individuals, and
both seniors and high-risk individuals when vaccine ef-
fectiveness was only moderate (40%) and coverage was
low (20%). Conversely, when vaccine effectiveness was
high (80%) and coverage was moderate (50%), vaccinat-
ing high risk individuals resulted in the highest iNMB.
Prioritisation by setting
Five of the included articles were single-country studies
modelling LMIC settings [14, 17, 19, 22, 46]. Four
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studies modelled UMIC settings [21, 23, 25, 33]. These
studies reached the same conclusions as the HIC studies
i.e. studies minimising deaths recommended prioritising
seniors, while those minimising cases recommended
prioritising high transmission groups. The exception was
one study from Thailand on minimising cases which rec-
ommended prioritising high transmission groups to min-
imise deaths [39].
There were also five multi-country studies which mod-
elled LMIC settings [8, 9, 12, 20, 24] and two modelling
UMIC settings [20, 29]. The conclusions for these stud-
ies were in line with the majority conclusions for deaths
and cases (except for one study which recommended
prioritising both the high social contact group and se-
niors to minimise deaths) [29]. See Additional file 1:
Table S6 for a summary of the studies modelling UMIC
and LMIC settings.
One study also considered prioritisation between
countries, in addition to within countries. This study
made recommendations on global vaccine allocation
strategies to optimise different health objectives [9]. The
authors concluded that the optimal strategy to minimise
deaths was to allocate doses equitably across all income
settings relative to population size and then to prioritise
vaccination of seniors within countries. This performed
better than allocating vaccines to countries based on
their respective senior population sizes, giving preferen-
tial allocation to HICs, giving preferential allocation to
LICs and LMICs, or allocating doses in proportion to
population plus providing a set number of extra doses to
HIC and UMICs [9]. When YLLs were used as an opti-
misation outcome measure, LMIC settings received the
most doses.
Factors that influence prioritisation strategy
40 out of 43 (93%) studies included a sensitivity analysis
(see Additional file 1: Table S7 for a summary of these
studies). Of these, 17 studies reported a sensitivity ana-
lysis that led to a potential change in the recommended
prioritisation strategy. While there were a wide range of
parameters tested in the uncertainty analysis, there were
only a few that consistently drove a change in prioritisa-
tion. The most common parameters that influenced pri-
oritisation all related to vaccine coverage, i.e. level of
vaccine supply, coverage, and speed of rollout (see Add-
itional file 1: Table S8 for a summary of coverage level
assumptions made by the exceptional studies to the ma-
jority of the study conclusions). Transmission rates and
vaccine efficacy were also considered.
Eight studies reported that the trade-off between direct
and indirect protection is sensitive to the proportion of
people vaccinated [9, 12, 15, 22, 27, 28, 38, 25]. These
papers stated that when vaccine supply is very low, vac-
cination has a minimal impact on interrupting
transmission, so more deaths can be prevented by vac-
cinating groups at risk of severe disease (e.g. essen-
tial workers, seniors, and clinical risk groups). However,
as supply increases, this opens up the possibility of inter-
rupting transmission, which shifts the optimal policy for
preventing deaths to prioritising the young or those with
many contacts. If there is very high vaccine supply, se-
niors are again favoured for prioritisation if aiming to re-
duce deaths, as there is sufficient coverage to achieve
both direct protection of the most vulnerable and indir-
ect protection of key transmitters. One study stated that
direct effects of immunisation take precedence in decid-
ing prioritisation when the vaccine supply is sufficient to
cover the priority groups in the study which make up
18% of the population (key workers, individuals with co-
morbidities, and the over-60s) [22].
The influence of COVID-19 transmission rates was
reported often in LMICs, but with varied results. One
study in India suggested that when the transmission rate
is low, those with comorbidities should be prioritised
over those aged over 60 years old [22]. In Brazil, model-
ling results suggested that the impact on deaths of vac-
cinating the young increases with earlier vaccination
dates, lower vaccine efficacy, and higher transmission
rates [23]. In Columbia, the presence of the Delta variant
reduced the magnitude of difference in the impact of
vaccinating different groups. However, in all papers, the
base-case result was to prioritise seniors [21].
Several studies tested different values of vaccine effi-
cacy, with most reporting before full results of vaccine
trials became available starting in late 2020. Generally,
variations in vaccine efficacy did not appear to change
prioritisation unless efficacy was significantly lower in
older rather than younger populations. However, a num-
ber of studies assumed that vaccines had similar levels of
efficacy against severe disease, infection, or transmission.
Where vaccines were more efficacious against severe dis-
ease strategies, the priority was to vaccinate highest
transmitters.
Discussion
We find that for countries seeking to minimise deaths,
the current evidence base supports prioritising vaccin-
ation of seniors (65+) as the optimal strategy, unless
there are exceptional cases where specific non-age-
related high-risk groups or very highly networked indi-
viduals can be identified and prioritised. The difference
in deaths averted can be large between depending on the
strategies, for example in this study, a symptom-
blocking vaccine with 50% uptake prioritising seniors
and high-risk groups averted 17,000 more deaths than
an unprioritised campaign [26]. For countries seeking to
minimise cases, the evidence supports prioritising young
age groups and essential workers. The evidence base
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examining the optimal strategy to improve health in
general is too limited to draw any firm conclusions. See
Additional file 1: Table S9 for a table showing how
much of the evidence base supported the WHO SAGE
vaccine prioritisation roadmap.
While in principle prioritising highly socially con-
nected groups may be optimal to reduce mortality, it
could prove difficult in practice to identify these groups,
especially when their definition and means of identifica-
tion are only vaguely defined [29, 30, 37, 38]. Chen et al.
suggest those population groups could be identified
through contact tracing, while recognising the limita-
tions of such an approach in resource constrained set-
tings [37]. Santini recommends prioritising younger
people with many connections to vulnerable people [30].
Buckner et al. find that prioritising essential workers
(based on occupation) could lead to fewer deaths in the
context of strong non-pharmaceutical interventions [34].
As no studies included the feasibility and costs of identi-
fying and delivering vaccines to highly connected groups,
it is unclear whether prioritisation to groups that are not
age or occupation-based is possible or cost-effective.
A study in Thailand examined how vaccines may be
prioritised in a low-incidence setting [39], finding that
prioritising younger age groups would lead to greater re-
ductions in deaths. This is similar to the study in India
which found that when transmission was low, the opti-
mal group to prioritise to reduce deaths shifted from
older people to those with comorbidities to increase in-
direct effects on transmission [22]. With two studies
modelling a low-incidence scenario in our sample, more
research may be required to validate this finding across
settings and modelling approaches. The small number of
studies set in low- and middle-income countries, and
the lack of evidence on the cost-effectiveness of reaching
different populations also limits our findings . Although
we found that most of the studies modelling these set-
tings were in line with the conclusions from studies set
in HIC for minimising deaths and cases, context may
impact results, especially when very limited supply is
considered. The studies based in LMIC settings assumed
a higher level of vaccine supply available and level of
coverage achieved than has been observed in most
LMICs (Additional file 1: Table S6). Further research is
urgently required to model the effect of different levels
of supply on prioritisation in lower income settings.
There was only one study modelling inter-country al-
location of vaccines [9], despite the political importance
of this issue [49]. That one study found that doses
should be allocated equally by the population size if
minimising deaths and allocated preferentially to low-
and middle-income countries if optimising life-years
gained. Since this differs drastically from the current
allocation of vaccine doses globally, it points to the need
for further investigation and action [9].
There were two studies modelling allocation of vac-
cines between geographical areas within the same coun-
try [45, 46]. One study concluded that geographical
areas of high disease burden should be prioritised for
vaccination [46], while the other concluded that the geo-
graphical areas of low disease burden should be priori-
tised [45]. The author’s interpretation of the latter result
is that in a scenario where vaccine supplies were low
and there was non-compliance to travel restrictions be-
tween geographical areas, the area of lower disease bur-
den was prioritised as it had a greater proportion of
susceptible individuals.
Only one study incorporated the impact of variants of
concern on vaccination prioritisation [21], possibly be-
cause most of our review focused on the time period up
to March 2021 only. The authors of this study in
Colombia were modelling the impact of age-based pri-
oritisation strategies of vaccination (oldest first) in the
context of variants and social mixing. In a scenario
where the delta variant became dominant after mid-
September 2021, age prioritisation of vaccination be-
came less important than if delta became dominant by
mid-July due to higher levels of vaccine coverage. How-
ever, maintaining a 21-day interval between the first and
second dose without further delay became more import-
ant in the September scenario due to the characteristics
of the delta variant [21].
Our review found that the optimal prioritisation strat-
egy to pursue depends on the public health objective(s)
of the decision-maker, with different conclusions de-
pending on whether the objective is reducing cases or
reducing mortality [37, 38]. The trade-offs between dif-
ferent objectives are a challenging ethical issue for
decision-makers.
The WHO SAGE value framework for the allocation
and prioritisation of vaccines proposed 6 principles as
the ethical basis of decisions on vaccine prioritisation:
the promotion of human well-being, equal respect, glo-
bal equity, national equity, reciprocity, and legitimacy
[2]. Within the framework, reducing disease burden
overall (and not purely the number of deaths) is a key
consideration to promote human wellbeing. However,
only one study considered integrated burden of disease
outcomes such as QALYs that combine both morbidity
and mortality in relation to prioritisation [11], one study
considered DALYs [19]. This evidence gap may be par-
ticularly limiting in settings with a younger population,
such as in many low- and middle-income countries,
where overall mortality may be a smaller proportion of
the overall COVID-19-related burden morbidity com-
pared to high-income countries.
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Only one study considered within-country equity
(such as prioritising populations that have suffered
disproportionately from COVID-19 because of their
socioeconomic status) [43]. We also consider the few
economic studies, such as economic evaluations, to
represent a research gap. The choice of one vaccine
strategy over another in the studies evaluated often
only took into account the net health gain, yet the
choice of the most appropriate vaccination strategy
should take into account health benefits, costs, and
the willingness to pay threshold—which varies in each
setting [50].
Our findings are limited by several methodological
issues. By limiting our search to English language
studies, we may have missed relevant studies, particu-
larly in low- and middle-income countries. Much of
this literature is pre-print studies which are not peer-
reviewed, so the quality of the evidence presented
here should be viewed with caution. Furthermore, the
included studies mainly reflect the earlier stage of the
pandemic up to March 2021, and variants of concern
were not well accounted for in the modelling litera-
ture at that time. This may have had implications on
which group to prioritise for vaccination considering
differences of transmissibility between variants. Fi-
nally, to highlight key findings across all studies, we
categorised the reviewed studies according to the
broad public health objectives that they aimed to ful-
fil. However, this categorisation may have obscured
some nuances within studies, such as where there
were variations in study conclusions grouped under
the same category.
Conclusion
The findings of this systematic literature review have
provided empirical evidence for the prioritisation of se-
niors for vaccination to minimise COVID-19 deaths and
young people to minimise COVID-19 transmission.
However, there remain critical gaps in the evidence
around strategies that reduce overall health outcomes,
considering the costs of different prioritisation strategies
and for low- and middle-income settings. The research
gaps identified can help to guide the direction of further
research on vaccination prioritisation as the pandemic
continues to evolve.
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